What do systematic reviews say?

Higher BP target (< 150‐160/95‐105 mmHg) vs lower BP target (< 140/90 mmHg)

Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).

• Blood pressure targets for hypertension in older adults 2017 · Cochrane Headline outcomes only
  RR 1.19 [0.98, 1.45]
  3 studies · 8221 participants
  Low

Naftopidil vs tamsulosin

Naftopidil showed no clear difference in cardiovascular adverse events compared with tamsulosin (alpha‐blocker) (low certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 0.97 [0.52, 1.8]
  9 studies · 824 participants
  Low

Naftopidil vs silodosin (alpha‐blocker)

Naftopidil showed no clear difference in cardiovascular adverse events compared with silodosin (alpha‐blocker) (low certainty).

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  RR 0.98 [0.39, 2.44]
  5 studies · 808 participants
  Low

Silodosin vs naftopidil

Silodosin showed no clear difference in cardiovascular adverse events compared with naftopidil (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.02 [0.41, 2.56]
  5 studies · 808 participants
  Low

Silodosin vs alfuzosin

Silodosin showed no clear difference in cardiovascular adverse events compared with alfuzosin (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 0.67 [0.36, 1.24]
  1 study · 60 participants
  Low

Silodosin vs placebo

It is very uncertain whether silodosin changes cardiovascular adverse events compared with placebo (very low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 1.28 [0.67, 2.45]
  4 studies · 1967 participants
  Very low

Silodosin vs tamsulosin

Silodosin showed no clear difference in cardiovascular adverse events compared with tamsulosin (low certainty).

• Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2017 · Cochrane Headline outcomes only
  RR 0.77 [0.53, 1.12]
  11 studies · 1955 participants
  Low

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  GRADE not reported

Naftopidil vs Eviprostat (phytotherapy)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  GRADE not reported